Pancreatic Cancer Therapeutics Market size was valued at USD 3,834 million in 2021 and is expected to reach USD 6,787.6 million by 2028, at a CAGR of 8.5% during the forecast period 2022 to 2028. Pancreatic cancer is the disease characterized by the abnormal proliferation of tumor cells in the pancreas leads to hinder in the pancreas function. Pancreatic cancer is majorly classified into 2 types namely exocrine cancers and neuroendocrine cancers. Symptoms associated with the pancreas cancer include jaundice, weight loss, abdominal pain, and diarrhea. Pancreatic cancer mainly occurs due to the consumption of tobacco and alcohol, smoking, obesity, and family history of pancreatitis. Pancreatic cancer can be diagnosed by using the MRI, CT scan, and ultrasound techniques and can be prevented by chemotherapy, radiotherapy, and surgery. Global Pancreatic Cancer Therapeutics Market is growing at a significant CAGR owing to increase in the prevalence of pancreatic cancer and increase in R&D activities for the innovation of newer therapeutics. Increase in the government funding and huge investments from the private sector for R&D activities is anticipated to propel the market growth. Acquisitions & mergers, collaborations, product pipeline are the key factors driving the market players revenue growth inGlobal Pancreatic Cancer Therapeutics Market. For instance, in December 2015, Boehringer Ingelheim collaborated with MD Andersen Cancer Centre for the development of newer therapeutics for pancreatic cancer. Similarly, in September 2013, Celgene received FDA approval for Abraxane used for the treatment of pancreatic cancer.